Abstract| Volume 18, ISSUE 6, SUPPLEMENT , S17, June 2016

Enabling Human Pluripotent Stem Cell Derived Megakaryocyte Manufacture

      Annually there are 4.5 million platelet transfusions in Europe and the United States. These are obtained solely from donors and have a shelf life of only a few days. It is estimated that demand will outstrip supply by 20% in some nations. To address this, the Ghevaert group at the University of Cambridge has devised a novel process for producing platelets by a transcription factor based forward programming approach of human pluripotent stem cells (hPSCs) into platelet producing precursor cells, the megakaryocytes (MKs). This strategy has the unique advantage of generating high yields of pure MKs in chemically defined medium through the establishment of 2–3 month long-term cultures. This could lead to the production of a consistent, reliable supply of platelets which overcomes the logistical, financial and biosafety challenges for health organisations worldwide. However, to enable commercialisation of platelet manufacture, process optimisation and scale-up is essential.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect